Form 4: MANGOCEUTICALS CFO Sells Shares Under 10b5-1 Plan

MANGOCEUTICALS, INC. CFO Eugene M Johnston reported the sale of 3,333 shares of common stock at $1.1653 per share, executed under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Eugene M Johnston, the Chief Financial Officer (CFO) of MANGOCEUTICALS, INC. (MGRX), reported an insider transaction.
• On December 15, 2025, Johnston sold 3,333 shares of MANGOCEUTICALS, INC. common stock.
• The shares were sold at a price of $1.1653 per share.
• This transaction was conducted pursuant to a Rule 10b5-1 trading plan, indicating it was pre-scheduled.
• Following this sale, Johnston directly beneficially owns 120,000 shares of MANGOCEUTICALS, INC. common stock.

Sentiment

Score: 5

Explanation: The filing reports a routine insider stock sale executed under a pre-arranged 10b5-1 plan. This type of transaction is generally considered neutral as it's often for personal financial management and not indicative of management's view on the company's immediate prospects.

Future Outlook

This Form 4 filing reports a past insider transaction and does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This insider transaction is a routine disclosure and does not provide specific insights into broader industry trends or competitive landscape. Insider sales, especially those under Rule 10b5-1 plans, are common and do not necessarily reflect a change in the company's or industry's fundamental outlook.

Comparison to Industry Standards

• N/A. This filing is a standard insider transaction report and does not contain information suitable for comparison to industry-specific benchmarks or competitor performance.

Stakeholder Impact

• Shareholders: A minor reduction in insider ownership, but the pre-planned nature and small size mitigate concerns about management confidence.
• Employees, Customers, Suppliers, Creditors: No direct impact from this routine insider transaction.

Key Dates

Recommendation

The reported sale by the CFO is a routine insider transaction executed under a Rule 10b5-1 plan, which typically indicates a pre-scheduled sale for personal financial planning rather than a reaction to new company developments. The amount sold is a small fraction of the CFO's remaining holdings, suggesting no significant change in confidence. Therefore, this filing alone does not provide a strong signal for a 'buy' or 'sell' recommendation, warranting a 'hold' position based solely on this information.

Keywords

MANGOCEUTICALS, MGRX, Insider Trading, Form 4, Stock Sale, CFO, Eugene M Johnston, Rule 10b5-1 Plan, Beneficial Ownership